In the following video, Motley Fool health-care analyst David Williamson discusses Depomed's (ASRT -1.76%) major FDA advisory committee embarrassment. The company's menopause drug Sefelsa received a nearly unanimous vote against it, not based on risk vs. reward, but on efficacy. Depomed paid $1 million for the opportunity to be reviewed by the panel. In the video, David tells investors how the company could have made such a miscalculation, why it could be a win on the market if the drug were to be approved, but why it's such a long shot that it isn't worth the risk, and what else Depomed has in its arsenal.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.